Ocugen (OCGN) Cash & Equivalents (2014 - 2025)

Ocugen's Cash & Equivalents history runs 12 years deep, the most recent figure standing at $37.8 million for Q1 2025.

• Quarterly Cash & Equivalents rose 43.32% year-over-year to $37.8 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $37.8 million (up 43.32% YoY) and the FY2023 annual result came in at $39.5 million, down 49.12% from the prior year.
• Cash & Equivalents was $37.8 million for Q1 2025 at Ocugen, up from $15.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $129.8 million in Q1 2022 and bottomed at $15.7 million in Q2 2024.
• A 5-year average of $73.2 million and a median of $70.6 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2021 — Cash & Equivalents surged 1302.82% — and 2024, when it slumped 77.76%.
• Ocugen's Cash & Equivalents stood at $95.0 million in 2021, then retreated by 18.32% to $77.6 million in 2022, then slumped by 49.12% to $39.5 million in 2023, then slumped by 60.22% to $15.7 million in 2024, then jumped by 140.81% to $37.8 million in 2025.
• Business Quant data shows OCGN's Cash & Equivalents at $37.8 million in Q1 2025, $15.7 million in Q2 2024, and $26.4 million in Q1 2024.